Vera Therapeutics, Inc.
Financials
Valuation Metrics
Vera Therapeutics, Inc.'s Market Cap is $2.17B. At end of 2025 it was $3.25B. Ranked #1942 of 3,114 in US market (top 62%), #726 of 1,469 on NASDAQ (top 49%), #130 of 265 in Pharmaceuticals, Biotechnology & Life Sciences (top 49%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | $2.17B | US#1,942/3,114 Sec#130/265 |
| Revenue | $0.00 | US#2,862/3,114 Sec#194/265 |
| Net Income | $-402M | US—/3,114 Sec—/265 |
| Total Assets | $533M | US#2,736/3,114 Sec#155/265 |
| Net Assets | $408M | US#2,355/3,114 Sec#133/265 |
| Employees | 361 | US#2,363/3,114 Sec#103/265 |
| Value | ||
| P/B | 5.33x | US#2,251/3,114 Sec#149/265 |
| FCF Yield | -15.61% | US—/3,114 Sec—/265 |
| Profitability | ||
| ROE | -98.56% | US#2,783/3,114 Sec#204/265 |
| ROA | -75.40% | US#3,037/3,114 Sec#244/265 |
| Financial Health | ||
| Debt Ratio | 30.71% | US#347/3,114 Sec#107/265 |
| Total Debt | $75M | US#2,511/3,114 Sec#133/265 |
| FCF | $-339M | US#2,872/3,114 Sec#241/265 |
| Cash | $49M | US#2,580/3,114 Sec#225/265 |
| Current Ratio | 10.92x | US#226/3,114 Sec#69/265 |
| Performance | ||
| 1Y Return | 6.32% | US#1,883/3,114 Sec#158/265 |
| 1M Return | -0.53% | US#2,705/3,114 Sec#202/265 |
| From 52W High | -46.01% | US#2,581/3,114 Sec#192/265 |
| 1Y MDD | -51.97% | US#2,461/3,114 Sec#171/265 |
| Trading | ||
| Volume | 1,603,317 shares | US#785/3,114 Sec#63/265 |
| Trading Value | $50M | US#1,089/3,114 Sec#63/265 |
| Per Share | ||
| EPS | $-5.60 | US—/3,114 Sec—/265 |
| BPS | $5.68 | US#2,217/3,114 Sec#119/265 |
Company Info
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A nephropathy. The company is also advancing MAU868, a monoclonal antibody in Phase 2 clinical development, designed to combat BK viremia infections. Founded in 2016 and based in Brisbane, California, the organization operated as Trucode Gene Repair, Inc. until it rebranded to Vera Therapeutics, Inc. in April 2020.